Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A promising start for SO-C101
September 2020
SHARING OPTIONS:

PRAGUE, Czech Republic—SOTIO and Cytune Pharma, two PPF Group-owned companies, shared preclinical data regarding SO-C101 at this year’s 2020 American Association for Cancer Research Virtual Meeting II. SO-C101 is an IL-15 superagonist being advanced as a potential therapy for advanced solid tumors, with Cytune Pharma handling clinical development and SOTIO sponsoring a Phase 1 clinical trial. The data that were presented focused on SO-C101’s antitumor efficacy in mouse models. The candidate demonstrated efficacy in treating established tumors and decreasing the rate of tumor development in an early treatment setting, with its effects dependent on NK and CD8+ T cells in both cases. According to the abstract, “This effect was durable, and the new tumor development was further significantly delayed after a tumor cell re-challenge, which suggests the involvement of memory T cells despite an important NK cell role in anti-tumor efficacy in these models.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.